Spero Therapeutics (SPRO) Net Margin (2016 - 2026)
Spero Therapeutics posted quarterly Net Margin of 2791.47% for Q1 2026, down 255540.0% year-on-year from N/an in Q1 2025, and down 550.84% on a QoQ basis from 428.9% in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Net Margin data on file, last reported at 2791.47% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 255540.0% year-over-year to 2791.47%; the trailing twelve-month figure through Mar 2026 stood at 121.45% (up 29606.0% YoY), and the FY2025 full-year result was 67.98%, up 21102.0% from the prior year.
- Net Margin for Q1 2026 stood at 2791.47%, down from 428.9% in the prior quarter.
- Across five years, Net Margin topped out at 163.85% in Q4 2022 and bottomed at 27232.31% in Q3 2024.
- The 5-year median for Net Margin is 428.9% (2025), against an average of 2487.67%.
- The widest annual swing landed in 2024, when Net Margin sank 2576671 bps; it then surged 2709662 bps in 2025.
- A 5-year view of Net Margin shows it stood at 163.85% in 2022, then tumbled by 49 bps to 84.08% in 2023, then sank by 195 bps to 79.57% in 2024, then slumped by 439 bps to 428.9% in 2025, then plunged by 551 bps to 2791.47% in 2026.
- The last three Net Margin figures came in at 2791.47% (Q1 2026), 428.9% (Q4 2025), and 135.69% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.65% |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -2,791.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,791.47% |
| Dec 31, 2025 | -428.90% |
| Sep 30, 2025 | -135.69% |
| Jun 30, 2025 | -12.01% |
| Mar 31, 2025 | -236.07% |
| Dec 31, 2024 | -79.57% |
| Sep 30, 2024 | -27,232.31% |
| Jun 30, 2024 | -302.61% |
| Mar 31, 2024 | -136.56% |
| Dec 31, 2023 | 84.08% |
| Sep 30, 2023 | -1,465.60% |
| Jun 30, 2023 | -438.44% |
| Mar 31, 2023 | -5,947.98% |
| Dec 31, 2022 | 163.85% |
| Sep 30, 2022 | -571.64% |
| Jun 30, 2022 | -1,303.01% |
| Mar 31, 2022 | -1,456.50% |
| Dec 31, 2021 | -177.61% |
| Sep 30, 2021 | -3,168.64% |
| Jun 30, 2021 | -876.54% |
| Mar 31, 2021 | -264.45% |
| Sep 30, 2020 | -49,976.32% |
| Jun 30, 2020 | -1,064.85% |
| Mar 31, 2020 | -1,327.69% |
| Dec 31, 2019 | -3,672.84% |
| Sep 30, 2019 | -378.68% |
| Jun 30, 2019 | -19,828.36% |
| Mar 31, 2019 | -70.70% |
| Dec 31, 2018 | -626.42% |
| Sep 30, 2018 | -1,590.12% |
| Jun 30, 2018 | -2,150.32% |
| Dec 31, 2017 | -1,487.41% |
| Sep 30, 2017 | -2,022.78% |
| Jun 30, 2017 | -4,867.87% |
| Mar 31, 2017 | -5,092.86% |
| Dec 31, 2016 | 12,820.00% |
| Sep 30, 2016 | -7,410.00% |